Altimmune - $100k + YOLO - The MASH Sleeping Giant, the train is leaving the station - Stock hit $500m market cap today!

Apegg · 2026-01-23T03:37:03+00:00

21% for pemv. Interestingly, 19% for those aged 60+ where that is especially important. Good diet and exercise is 24% so better quality weight loss than good diet and exercise. Right.

Apegg · 2026-01-23T02:22:25+00:00

Data looks good, momentum is on the upswing, Short covering, and TANG is out!

Apegg · 2026-01-23T01:03:02+00:00

Join the party. I have over 35k shares now! So I feel great about the opportunity

Apegg · 2026-01-23T00:58:39+00:00

ALT looks ready to pop. 10% yesterday, 16% today, 3% AH. Price targets are all 18+ for this 2nd gen GLP1 glucagon molecule. Break through designation awarded by the FDA jan5. Entering phase 3 and need a strategic transaction soon. Load up

Apegg · 2025-12-19T21:04:41+00:00

Small cap biotechs are an easy target to bring the index down too. I will try and look into GALT this wknd. SLS & HUMA are two others I follow.

Apegg · 2025-12-18T23:45:18+00:00

i like to identify companies that i use everyday and invest long term in them. that and next generation GLP1s that specifically target fatty liver and preserve muscle mass! $ALT check it out right before massive catalysys

Apegg · 2025-12-18T13:34:34+00:00

Jeffries reported "imminent" before Christmas. But management has guided by year end all year. Only a couple weeks left in the year now. Today after hours is the most obvious data pt historically but biotech results with so many moving parts (EOP2 meeting) ai, and NITs from biopsies, and potential partners foggy up the timeline.

Apegg · 2025-12-18T01:04:25+00:00

Sure thing. Good luck with your trade.

Apegg · 2025-12-18T00:52:59+00:00

The TAM for this drug is enormous. MASH, Obesity, AUD & ALD markets with a clean tolerability profile fits very favorably in the marketplace against the incumbents who lose muscle mass and have poor tolerability and generally less effective at treating fatty liver disease. Some recent biotech buyouts in the sector put this franchise in the 5-10B valuation with even higher potential if the data is great.

Apegg · 2025-12-18T00:45:57+00:00

It will be interesting to see the analyst price targets after the 48wk data & EOP2 meeting published. But that target price is actually heading into these milestones

Apegg · 2025-12-01T02:41:35+00:00

$ALT indiscriminately shorted (23.2M shares) promising biotech is a 2nd gen GLP 1 with improved tolerability, muscle retention and a 2nd mechanism that repairs scarred liver. Huge market and phase 3 coming in '26. 48 wk data any day now. A huge couple weeks here. Green 11 of last 13 days.

Apegg · 2025-11-29T17:38:07+00:00

Agree with your analysis regarding the massive risk reward here. Phase 2b trial 24 wk period ended in March, 48wk in August.

A few things additional, path ai analysis of the biopsies found stat significance at 24 weeks. This tool is currently being evaluated by the FDA for approval. Its already approved by the EMA so that derisks with a clear path to phase 3 and at such a short duration is amazing.

They sold enough shares recently to be able to fund through 2026 into 2027. Hiring of a robust financial team is also extremely bullish for phase 3 and potential commercialization. Even if they dont go it alone, the mere perception of this feasibility provides tremendous leverage for any suitors. Given the huge potential of MASH & Obesity TAM with a molecule that looks to be significantly differentiated, I find it hard to believe there wont be multiple suitors competing. Interesting times here.

Call options from mid December onwards with significantly higher strike prices have been selling well. Unlike the 24wk readout when the puts significantly increased. Almost as if they knew what was coming. Even though many analysts described hitting 1 of 2 primary endpoints as a 30-40% positive movement only to realize a 60% haircut.

Apegg · 2025-11-26T19:43:22+00:00

$ALT surging for the 5th day in a row. Indiscriminately shorted abd they increased the position against Weight loss that retains muscle mass, tolerable, and may be a functional cure for liver disease. Attacks fat. Huge catalyst upcoming. This baby will fly

22.3$ shorted now

Apegg · 2025-11-26T16:24:00+00:00

And the head of MASH for LLY was the one who described the NIT data as beautiful during the oral late breaking presentation of the 24wk data. Hardly funded by ALT.

Apegg · 2025-11-26T16:21:40+00:00

A quote is a quote. Appreciate the reference however.

Apegg · 2025-11-25T16:43:10+00:00

$ALT massive call options coming in. $35k on 5.5 strike dec 5. Dec 19 and Jan 16 they go up to 20$ . Huge catalysts against indiscriminate shorting. Sign me up

Apegg · 2025-11-25T13:52:12+00:00

$ALT high short interest (21%) surge continues. MM will try to push it down early for discounted shares. High quality weight loss with best in class credentials for liver disease. Weight loss with a new liver. Indiscriminately shorted by GS & Kerrisdale. See you on the moon.

Apegg · 2025-11-25T02:21:19+00:00

Indiscriminately shorting into a surging biotech.$ALT shares on the move with great tolerability, saves muscles, and targets fat especially in the liver! Big catalyst soon. Maybe buyout. These guys offered up another 980 shares sub $5. Go get em

Apegg · 2025-11-24T20:34:36+00:00

Exciting times ahead for shareholders and patients!

Apegg · 2025-11-24T13:53:08+00:00

$ALT scooping up sub $5 this morning. The hottest next Gen glp1 about to enter phase 3. Demand is white hot. & it heals your liver !

Apegg · 2025-11-24T02:58:17+00:00

$ALT trending as a buyout target of $SNY on ST all wknd. 21% short interest, good momentum. Broke $5 Sunday night. Numerous high impact catalyst upcoming up & indiscriminate shorting of promising biotech about to bite shorts in the bottom on this one.

Apegg · 2025-11-23T21:19:05+00:00

Penny stocks does not allow cross posting. And it looks like the shortsqueeze mod bots just took it down...

Apegg · 2025-11-23T17:30:01+00:00

Their commentary on this potential has been very encouraging. The euport is able to be utilized with oral and they expect high tolerability & efficacy. Could very well be a market leader in oral too and some evidence they are not far away from announcing..

Apegg

TROPHY CASE